))
DME/Retina Edition: Top Headlines for Week of June 3, 2024
Manage episode 422229053 series 3560281
İçerik Healio tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Healio veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:
VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema
VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME
Phase 2 study of potential DME oral therapy meets primary endpoints
FDA approves aflibercept biosimilars Yesafili, Opuviz
References:
Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.
120 bölüm
Paylaş
